Table 1.
Patient characteristics of the NSCLC cohort studied. 4,706 (27.5%) samples of the entire cohort (17,095) had a KRAS mutation. Each KRAS mutation subtype is listed along with the frequency of patients harboring each subtype, the female versus male distribution, as well as the age range and median age.
| Total N (%) | Female N (%) | Male N (%) | Median age | Age range | |
|---|---|---|---|---|---|
| KRAS WT | 12,389 (72.5) | 5,862 (47) | 6,527 (53) | 68.0 | 20–97 |
| All KRAS mutation | 4,706 (27.5) | 2,677 (57) | 2,029 (43) | 68.0 | 22–97 |
| G12C | 1,882 (40) | 1,102 (59) | 780 (41) | 68.0 | 27–95 |
| G12V | 915 (19) | 504 (55) | 411 (45) | 68.0 | 37–92 |
| G12D | 684 (15) | 386 (56) | 298 (44) | 69.0 | 22–97 |
| G13 | 327 (7) | 184 (56) | 143 (44) | 67.0 | 41–90 |
| Q61 | 313 (7) | 175 (56) | 138 (44) | 69.0 | 40–90 |
| G12A | 298 (6) | 160 (54) | 138 (46) | 70.0 | 37–90 |
| G12 Other | 210 (4) | 130 (62) | 80 (38) | 68.0 | 35–91 |
| Other | 77 (2) | 36 (47) | 41 (53) | 68.0 | 37–89 |
| Total | 17,095 | 8,539 (50) | 8,556 (50) | 68.0 | 20–97 |